Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
about
Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell DissociationMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cellsBRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.High-throughput detection of clinically targetable alterations using next-generation sequencing.Suppression subtractive hybridization identified differentially expressed genes in colorectal cancer: microRNA-451a as a novel colorectal cancer-related gene.Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Neomorphic mutations create therapeutic challenges in cancer.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma.Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.Report and Application of a Tool Compound Data Set.Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.Molecular Biomarkers for the Evaluation of Colorectal Cancer.Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.Design, Synthesis and Biological Activity Evaluation of S-Substituted 1-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal CancerSynthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade SignalingNew Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
P2860
Q28067118-71E8DE03-6EA3-419A-AF12-468ECFDE07C9Q28076490-6DDB446E-C580-4B4D-B9D7-92934434DE9FQ33601377-5AFB78BB-34AA-47CE-8D2E-35BA347571A6Q33733048-B83693C1-DD85-4F29-98DF-9561817D3043Q35962621-94FABD15-6BE4-4FEE-A342-C5DE002EC486Q36345358-3294A499-F509-4281-A5A3-ACE0277F396BQ36362412-D8E43489-C69B-458F-BB0E-BF5248517DADQ37165886-D3B4FB23-68A3-45A5-AF6E-976C1D957938Q37544392-ED6570BE-ECB2-406A-9FFD-B5B55FB7D2DAQ37725589-66ABD56B-486A-4006-BD57-B930F3E3F338Q39007820-3FF29022-0E2C-4943-948D-57D160794CFBQ40341349-918330D9-91AE-4208-B700-EAECC88FBBE8Q42705608-5D5ED54D-E648-45C2-8156-0074C8C7D8FDQ47100954-8372C6EC-E9AE-4D24-8548-3BB49BAD1F12Q47648532-AFDEAE3A-DBBA-4AA9-8220-EF7DC7449CAEQ47760790-6518D250-0A94-4C0B-8F15-5EE56005202BQ49417294-11CE06AA-2A4E-4BE7-BFDD-EE89978A8E7DQ51744124-8EB21CBA-0E2E-47E6-BBC5-208DA40F52FBQ52794464-9F160F73-7ADD-464C-8717-C31C8956AA1BQ52839686-679BAAB0-7EC1-4514-B639-91571B78C7D8Q53705974-4E78AA39-E07D-4750-A387-398EE83EC347Q55332287-FF2531A2-27BD-4DEF-B9E6-FD8271F0B552Q57167787-D0C34455-5A1E-4218-8CD8-A5A51EE06CC4Q57490053-5D05F86B-80DD-467B-9CA7-D0A873E70555Q58801701-700E8898-DD4B-4B78-A5EA-AA0A78E78469
P2860
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@ast
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@en
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@nl
type
label
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@ast
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@en
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@nl
prefLabel
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@ast
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@en
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@nl
P2860
P921
P3181
P356
P1476
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
@en
P2093
Ali Shamseddine
Deborah Mukherji
P2860
P304
22976-22988
P3181
P356
10.3390/IJMS160922976
P407
P50
P5008
P577
2015-09-23T00:00:00Z